University of Groningen

A systematic review of instruments to measure depressive symptoms in patients with schizophrenia

Lako, Irene M.; Bruggeman, R.; Knegtering, H.; Wiersma, D.; Schoevers, R. A.; Slooff, C. J.; Taxis, K.

Published in:
Journal of Affective Disorders

DOI:
[10.1016/j.jad.2011.10.014](https://doi.org/10.1016/j.jad.2011.10.014)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lako, I. M., Bruggeman, R., Knegtering, H., Wiersma, D., Schoevers, R. A., Slooff, C. J., & Taxis, K. (2012). A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. *Journal of Affective Disorders*, 140(1), 38-47. <https://doi.org/10.1016/j.jad.2011.10.014>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Review

A systematic review of instruments to measure depressive symptoms in patients with schizophrenia

Irene M. Lako^{a,b,1}, R. Bruggeman^{a,b,c,2}, H. Knegtering^{a,d,3}, D. Wiersma^{a,4}, R.A. Schoevers^{a,c,5}, C.J. Slooff^{a,e,6}, K. Taxis^{b,*}

^a Rob Giel Research Center (RGOc), Department of Psychiatry (UCP), University Medical Center Groningen (UMCG), University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands

^b Department of Pharmacy, Division of Pharmacotherapy and Pharmaceutical Care, University of Groningen, A. Deusinglaan 1, 9713AV, Groningen, The Netherlands

^c Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands

^d Lentis Center for Mental Health Care and UMCG Neuroimaging Center, University of Groningen, Hereweg 80, 9725 AG, Groningen, The Netherlands

^e Department of Psychotic Disorders, Mental Health Centre Assen (GGZ Drenthe), Dennenweg 9, 9404 LA, Assen, The Netherlands

ARTICLE INFO

Article history:

Received 23 September 2011

Received in revised form 11 October 2011

Accepted 11 October 2011

Available online 17 November 2011

Keywords:

Schizophrenia

Depressive symptoms

Instrument

Psychometric properties

Validity

ABSTRACT

Background: Depressive symptoms require accurate recognition and monitoring in clinical practice of patients with schizophrenia. Depression instruments developed for use in depressed patients may not discriminate depressive symptoms from negative psychotic symptoms.

Objective: We reviewed depression instruments on their reliability and validity in patients with schizophrenia.

Methodology: A systematic literature search was carried out in three electronic databases. Psychometric properties were extracted for those instruments of which reliability, divergent, concurrent and predictive validity were reported in one or more publications.

Results: Forty-eight publications described the reliability and validity of six depression instruments in patients with schizophrenia. The only self-report was the Beck Depression Inventory (BDI). The Brief Psychiatric Rating Scale–Depression subscale (BPRS-D), Positive and Negative Syndrome Scale–Depression subscale (PANSS-D), Hamilton Rating Scale for Depression (HAM-D), Montgomery Asberg Depression Rating Scale (MADRS) and Calgary Depression Scale for Schizophrenia (CDSS) were clinician rated. All instruments were reliable for the measurement of depressive symptoms in patients with schizophrenia. The CDSS most accurately differentiated depressive symptoms from other symptoms of schizophrenia (divergent validity), correlated well with other depression instruments (concurrent validity), and was least likely to miss cases of depression or misdiagnose depression (predictive validity).

Conclusions: We would recommend to use the CDSS for the measurement of depressive symptoms in research and in daily clinical practice of patients with schizophrenia. A valid self-report instrument is to be developed for the use in clinical practice.

© 2011 Elsevier B.V. All rights reserved.

* Corresponding author. Tel.: +31 50 3638205; fax: +31 50 3632772.

E-mail addresses: i.m.lako@umcg.nl (I.M. Lako), r.bruggeman@umcg.nl (R. Bruggeman), h.knegtering@lentis.nl (H. Knegtering), duirk.wiersma@umcg.nl (D. Wiersma), r.a.schoevers@umcg.nl (R.A. Schoevers), cees.slooff@ggzdrenthe.nl (C.J. Slooff), k.taxis@rug.nl (K. Taxis).

¹ Tel.: +31 50 3638709; fax: +31 50 3632772.

² Tel.: +31 50 3612043; fax: +31 50 3632772.

³ Tel.: +31 50 5223782; fax: +31 50 4095795.

⁴ Tel.: +31 50 3613839; fax: +31 50 3632772.

⁵ Tel.: +31 50 3612065; fax: +31 50 3632772.

⁶ Tel.: +31 059 2272796; fax: +31 50 3632772.

Contents

1.	Introduction	39
2.	Methods	39
2.1.	Search procedure	39
2.2.	General information	40
2.3.	Reliability	40
2.4.	Divergent validity	40
2.5.	Concurrent validity	40
2.6.	Predictive validity	40
3.	Results	40
3.1.	Inclusion of studies	40
3.2.	General characteristics	41
3.3.	Reliability	43
3.4.	Divergent validity	43
3.5.	Concurrent validity	43
3.6.	Predictive validity	44
4.	Discussion	44
4.1.	Summary of results	44
4.2.	Reliability	44
4.3.	Validity	44
4.4.	Practical considerations	44
4.5.	Future research	44
4.6.	Recommendations and conclusions	44
	Role of funding source	45
	Conflict of interest	45
	Acknowledgements	45
	References	45

1. Introduction

Depressive symptoms are highly prevalent (25%) in patients with schizophrenia (Buckley et al., 2008; Siris and Bench, 2003). These comorbid depressive symptoms are associated with a higher burden of disease and more frequent relapses (Conley et al., 2007; Tollefson et al., 1999). Schizophrenia is a lifelong psychiatric disorder and depressive symptoms may occur through all phases of illness: during acute psychosis (Häfner, 2000; Leff et al., 1988) as well as after remission of psychosis (Birchwood et al., 2000). Recent literature suggests that depressive symptoms may also be understood as a dimension within the schizophrenia concept and that individual symptom profiles should guide treatment (Van Os and Kapur, 2009). Furthermore, the upcoming fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) advocates to measure psychopathology in terms of quantitative dimensions, instead of solely as discontinuous categories (<http://www.dsm5.org>). Adequate screening and monitoring of depressive symptoms is required to guide appropriate treatment (Bressan et al., 2003; Lako et al., 2011; Schennach-Wolff et al., 2011).

Measurement instruments can be helpful for screening and for monitoring of symptomatic changes (Möller, 2009). The assessment of depressive symptoms is complicated in patients with psychotic disorders, as they resemble “classic” symptoms of schizophrenia, such as negative symptoms and extrapyramidal symptoms (EPS) (Barnes and McPhillips, 1995; Harrow et al., 1994; Siris and Bench, 2003; Van Putten and May, 1978). Particularly drug-induced parkinsonism may resemble a depressed state (Norman and Malla, 1991). It is doubtful whether instruments, primarily developed for use among depressed patients, are able to selectively

discriminate depressive symptoms from other symptom dimensions in schizophrenia (divergent validity) (Allan and Martin, 2009; Fitzgerald et al., 2002). Currently there is no overview of available depression instruments and their psychometric properties in patients with schizophrenia.

This systematic review provides an overview of instruments that can be used for the screening on depressive symptoms (further referred to as “depression instruments”). Instruments are compared regarding their divergent validity and other psychometric properties in this patient population. This review may help in choosing a suitable instrument for the measurement of depressive symptoms in research as well as in daily clinical practice of patients with schizophrenia.

2. Methods

2.1. Search procedure

As a first step, titles and abstracts were screened on relevance for the defined topic and, if appropriate, the full paper was examined. Inclusion criteria were: 1) studies assessing psychometric properties of instruments measuring depressive symptoms in a population of patients with schizophrenia or non-affective psychotic disorders, 2) the availability of a validated English translation of the depression instrument and 3) publication in English, German, French or Dutch language. Unidimensional depression instruments (measuring a single dimension, in this case depressive symptoms), as well as multidimensional instruments measuring multiple symptom dimensions providing a subscale for depressive symptoms, were included. We refer to the depression subscale of a multidimensional instrument by the addition of [-D] to

the abbreviation of the instrument, for example BPRS-D. We excluded studies describing diagnostic instruments and instruments designed to measure related symptoms, such as anxiety or suicidality.

The following search terms were entered in the online databases PubMed, Embase and PsychINFO: (“depression” or “depressive symptoms”) and (“schizophrenia” or “psychosis” or “psychotic”) and (“instrument” or “rating scale” or “scale” or “questionnaire” or “interview”) and (“psychometric” or “reliability” or “validation” or “validity” or “reproducibility”). The search was carried out in May 2010. All retrieved studies were checked for cross-references.

2.2. General information

General information about the most recent version of each instrument was collected from (original) validation studies and the Handbook of Psychiatric Measures. In order to quantify the recent use of the selected instruments in research, we counted the number of studies published between May 2005 and May 2010. The composition of each depression instrument was explored as follows. Each item of an instrument was categorized under one of the nine diagnostic criteria for a Major Depressive Episode (MDE), defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association, 1994). Remaining items were categorized under three additional symptom dimensions: “delusional ideas,” “other vital symptoms” and “anxiety.” Four of the nine diagnostic criteria for MDE show overlap with symptom dimensions of schizophrenia, in particular negative symptoms and extrapyramidal symptoms. For each instrument, the number of potentially overlapping items was divided by the total number of items. This illustrated the instruments' ability to discriminate depressive symptoms from other symptom dimensions of schizophrenia.

Psychometric properties were extracted for those instruments of which reliability, divergent, concurrent and predictive validity were reported in one or more publications. In the next paragraphs we explain these psychometric properties.

2.3. Reliability

Reliability is generally estimated by internal consistency, inter-rater and test-retest reliability. Internal consistency reflects the coherence between items within an instrument. Corresponding Cronbach's alpha values of 0.60–0.70 are considered acceptable and values of >0.70 as good (Cicchetti, 1994). Good inter-rater and test-retest reliability is reflected by little variation between the scores by different raters and, respectively, by repeated measurements; these are commonly expressed by intra-class coefficients (ICC) >0.70.

2.4. Divergent validity

Divergent (or discriminant) validity refers to the extent that different symptom dimensions are unrelated to each other. Here, an instrument designed to measure depressive symptoms, should not measure negative symptoms, EPS or anxiety as well. Divergent validity is commonly expressed by the Pearson's product moment correlation (PPMC) between scores

on a depression instrument and scores on an instrument measuring another symptom dimension. Absent correlation with negative symptoms or EPS indicates good divergent validity. Nevertheless weak correlations (<0.30) are acceptable, as depressive symptoms tend to occur together with negative symptoms and EPS (Kulhara et al., 1989; Van Putten and May, 1978).

Divergent validity can also be evaluated on the stability of the underlying factor structure of a particular instrument across different samples. For multidimensional instruments, principal component factor analysis (PCA) should identify depressive symptoms as a separate factor from psychotic symptom dimensions. In addition, the content of this depression factor should remain stable by confirmatory factor analysis in different samples. PCA of unidimensional instruments in a population with schizophrenia should identify factors describing depressive symptom dimensions, but no psychotic symptom dimensions.

2.5. Concurrent validity

Concurrent (or convergent) validity refers to the extent that common symptom dimensions are in fact related. Concurrent validity is high when the scores on two instruments measuring the same symptom dimension correlate well (PPMC). Based on the mean correlation of each possible comparison between two instruments, we calculated a pooled mean correlation over all comparisons for each instrument.

2.6. Predictive validity

Predictive validity represents the accuracy of an instrument to correctly detect a case (here of depression). Included were publications using a validated diagnostic interview such as the Structured Clinical Interview for DSM-IV (First et al., 1995) as gold standard to identify positive cases of depression. Good predictive validity is reflected by high sensitivity (not likely to miss cases of depression) combined with high specificity (not likely to misdiagnose depression) at the optimal cut-off value, i.e. the best balance between sensitivity and specificity determined by area under the receiver operating curve methods (Hanley and McNeil, 1983).

3. Results

3.1. Inclusion of studies

The systematic search generated a total of 2642 articles, of which 57 publications were eligible for further evaluation (Fig. 1). For six depression instruments complete information on psychometric properties in a population with schizophrenia or psychotic disorders was described in forty-nine publications. These included two multidimensional instruments: the Brief Psychiatric Rating Scale, Expanded Version (BPRS) (Lukoff et al., 1986; Overall et al., 1972) and the Positive And Negative Syndrome Scale (PANSS) (Kay et al., 1987), and four unidimensional instruments: the Hamilton Rating Scale for Depression (HAM-D) (Hamilton, 1960), Montgomery Asberg Depression Rating Scale (MADRS) (Montgomery, 1979), Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1993) and Beck Depression Inventory-II (BDI) (Beck et al., 1996). The remaining 8 publications

Fig. 1. Flow diagram of publications identified in databases PsychINFO, Medline and PubMed with keywords for schizophrenia, depressive symptoms and psychometrics.

described depression instruments with incomplete information about their psychometric properties in schizophrenia. For example, no information was available on reliability or divergent validity in schizophrenia for the Brief Symptom Inventory (BSI) (Derogatis and Spencer, 1982) and Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff, 1977).

3.2. General characteristics

General characteristics of the six reviewed depression instruments are described in Table 1. Only one instrument

was based on self-report. Unidimensional instruments required on average 10 minutes less time to be completed than multidimensional instruments. The number of items per depression instrument varied between 4 and 21. A quantitative investigation of the use of these depression instruments over the past five years showed that the CDSS was most frequently used in research in this period, closely followed by the PANSS-D and the HAMD.

Table 2 illustrates the composition of the depression instruments in the context of schizophrenia. The depressive symptoms covered by the CDSS had minimal overlap with

Table 1
General characteristics of reviewed instruments.

	Symptom dimensions	Mode	Training	Duration (minutes)	Time-frame	Number of items	Likert scale	Recent use
BPRS	Multidimensional	Clin.r.	++	25–40	2 weeks	24	7	3
PANSS	Multidimensional	Clin.r.	+++	30–40	1 week	30	7	6
HAMD	Unidimensional	Clin.r.	+	20	3 days	17	5	5
MADRS	Unidimensional	Clin.r.	+	15	1 week	10	4	1
CDSS	Unidimensional	Clin.r.	++	15–20	2 weeks	9	4	6
BDI	Unidimensional	Self-r.	n.a.	10	2 weeks	21	4	4

BPRS = Brief Psychiatric Rating Scale; PANSS = Positive and Negative Syndrome Scale; HAMD = Hamilton Rating Scale for Depression; MADRS = Montgomery Asberg Depression Rating Scale; CDSS = Calgary Depression Scale for Schizophrenia; BDI = Beck Depression Inventory. Clin.r. = clinician rated; Self-r. = self-rated. The amount of training needed to standardize raters varied between + (reading the instructions and/or a single consensus training), ++ (a short training session, followed by ≥ 3 times of practice) and +++ (more than one day of training); n.a. = not applicable. Recent use was expressed by the number of publications reporting the use of an instrument for the measurement of depressive symptoms in patients with schizophrenia between 2005 and 2010.

Table 2

Composition of instruments evaluating depressive symptoms in schizophrenia.

Symptom dimensions	Symptoms	MDE criteria	BPRS-D	PANSS-D	HAMD	MADRS	CDSS	BDI
Depressive symptoms	Depressed mood ^a	1	1	1	1	3	4	4
	Changed appetite or weight	1	–	–	2	1	–	1
	Sleeping problems	1	–	–	3	1	1	1
	Worthlessness ^b	1	–	–	–	–	2	4
	Suicidal ideation	1	1	–	1	1	1	1
Negative symptoms	Loss of interest or pleasure	1	–	–	–	1	–	2
	Fatigue/lack of initiative or motivation	1	–	–	1	1	–	2
	Indecisiveness/lack of concentration	1	–	–	–	1	–	2
EPS	Psychomotor agitation or retardation	1	–	–	2	–	–	1
Other	Delusional ideas ^c	–	3	2	3	–	1	2
	Other vital symptoms ^d	–	–	–	2	–	–	1
	Anxiety/tension ^e	–	1	2	2	1	–	–
	Items identifying symptoms in non-depressive dimensions	4	4	4	10	4	1	10
	Total number of items of the (sub)scale ^f	9	6	5	17	10	9	21
% of items identifying non-depressive dimensions		44%	67%	80%	59%	40%	11%	48%

Depressive symptoms (dimensions) potentially overlapping with psychotic symptoms. a) Appeared or perceived depressed mood, including hopelessness, crying, pessimism, irritability and diurnal variation of mood. b) Including self-blame and non-delusional feelings of guilt. c) Including paranoid symptoms, hypochondriacal delusions, feeling criticized by others, poor insight and delusional feelings of guilt or punishment. d) Including loss of libido and somatization. e) Including obsessional and compulsory symptoms. f) Depression subscale of the BPRS as defined by [Dingemans et al. \(1995\)](#); depression subscale of the PANSS as defined by [Kay et al. \(2000\)](#).

other symptom dimensions of schizophrenia. In contrast, about three quarter of the items of the PANSS-D and BPRS-D showed overlap with anxiety and positive symptoms. The

HAMD contained many items on delusional symptoms. Almost half of the items of the MADRS and BDI could also be interpreted as negative symptoms.

Table 3

Aspects of reliability and validity of depression instruments in schizophrenia.

a. Reliability								
	Internal consistency		Inter-rater		Test-retest		References	
BPRS-D	0.67		0.74		0.72		(1,2)	
PANSS-D	0.77		0.80		–		(3,4)	
HAMD	0.75 (0.73–0.77)		0.94 (0.93–0.95)		0.75 (0.65–0.80)		(1,2,5–7)	
MADRS	0.91		0.81		0.71		(3,7,8)	
CDSS	0.82 (0.76–0.88)		0.86 (0.73–0.98)		0.83 (0.69–0.93)		(1,5–7,9–18)	
BDI	0.90 (0.88–0.91)		n.a.		–		(1,19)	
b. Divergent validity								
	Negative symptoms		References		EPS		References	
BPRS-D	0.00 (–0.11–0.10)		(2,20,21)		0.14 (0.07–0.21)		(22,23)	
PANSS-D	0.19 (–0.11–0.41)		(3,15,21,24–27)		0.07 (0.01–0.20)		(22,24–26)	
HAM-D	0.18 (0.02–0.45)		(2,15,21,23,24,26–31)		0.40 (0.02–0.79)		(14,22–24,26)	
MADRS	0.36 (0.12–0.51)		(3,15,23,25)		0.52 (0.16–0.86)		(14,23,25)	
CDSS	0.10 (–0.24–0.54)		(9,11–15,21,23,24,26,27,32,33)		0.26 (0.07–0.42)		(9,11,13,14,22–24,26,32,33)	
BDI	0.10 (–0.11–0.21)		(19,26,31,34)		0.23		(26)	
c. Concurrent validity								
	BPRS-D	PANSS-D	HAMD	MADRS	CDSS	BDI	Pooled mean	References
BPRS-D	0.23	0.66	0.66	0.79	0.64	0.60 (0.17–0.87)	(1,2,5,21,23,28,35,36)	
PANSS-D		0.62	0.72	0.66	0.49	0.54 (0.17–0.87)	(3,7,9,11,13,15,19,21,24–27,36)	
HAMD			0.80	0.74	0.57	0.68 (0.26–0.90)	(1,2,5,7,8,11,13–15,21,23,24,26–28,30,31,34,37)	
MADRS				0.81	–	0.75 (0.56–0.90)	(3,7,8,11,14,15,23,25)	
CDSS					0.83	0.77 (0.26–0.90)	(1,7,9,11–15,21,23,24,26,27,37)	
BDI						0.63 (0.44–0.90)	(1,5,12,19,26,30,31,34,35)	
d. Predictive validity								
	Sensitivity		Specificity		Cut-off value		References	
BPRS-D	–		–		–		–	
PANSS-D	78% (74–81%)		85% (79–90%)		≥5; ≥10		(15,26)	
HAMD	79% (67–91%)		83% (81–84%)		≥12		(15,26)	
MADRS	81%		81%		≥11		(15)	
CDSS	88% (67–100%)		88% (74–97%)		≥5; ≥6; ≥9		(1,9,11,15,26)	
BDI	72%		77%		≥25		(26)	

3.3. Reliability

The internal consistency of the BPRS-D was acceptable and good for the remaining instruments in schizophrenia (Table 3a). The inter-rater and test-retest reliability was good for all instruments, especially the inter-rater reliability of the HAMD.

3.4. Divergent validity

The MADRS correlated with negative symptoms and the HAMD with EPS, whereas the other reviewed instruments neither showed substantial correlation with negative nor extrapyramidal symptom dimensions (Table 3b). The following instruments were used for the rating of negative and extrapyramidal symptoms: Affective Flattening Scale (AFS) (Andreasen, 1979), Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1982), negative subscale of the PANSS (Kay et al., 1987), negative subscale of the BPRS (Lukoff et al., 1986; Overall et al., 1972), Psychomotor Retardation Scale (Widlocher, 1983), and Rating Scale for Extrapyramidal Side Effects (Simpson and Angus, 1970).

The underlying factor structure of the multidimensional instruments (BPRS and PANSS) generally consisted of one

factor for depression and two to four other factors. The depression factor was comprised of the three items “depression,” “guilt” and “anxiety” (Lykouras et al., 2000; McMahon et al., 2002), but additional items loading on the depression factor were “tension” (Lindenmayer et al., 1995; Van Der Gaag et al., 2006; White et al., 1997; Wolthaus et al., 2000), “somatic concern” (Eisenberg et al., 2009; El Yazaji et al., 2002; Lee et al., 2003; Loas et al., 1997) and “suicidality” (Kopelowicz et al., 2008; Ruggeri et al., 2005), or other combinations including “self neglect” (Dingemans et al., 1995) or “motor retardation” (Alves et al., 2005). Inspection of the factor structure of the MADRS and the CDSS did not lead to separate factors for negative symptoms (Lee et al., 2003; Maggini and Raballo, 2006; Wolthaus et al., 2000). The BDI consisted of three factors, including one for “psychosomatic symptoms” (Chemerinski et al., 2008). Of note, no publications reported the factor structure of the HAMD in patients with schizophrenia.

3.5. Concurrent validity

The concurrent validity of the depression instruments in schizophrenia is described in Table 3c. Concurrent validity has been assessed for almost every possible combination of

Notes to Table 3:

a) Reliability was expressed by mean Cronbach's alpha and ICC values; n.a. = not applicable. b) Mean correlation (R^2) with either a negative symptom scale or extra-pyramidal symptoms rating scale. c) Average correlation for each comparison of two depression instruments and the pooled mean correlation indices for each instrument. d) Mean sensitivity and specificity values at the optimal cut-off point. References:

1. Addington et al. (1993)
2. Craig et al. (1985)
3. Wolthaus et al. (2000)
4. Haro et al. (2003)
5. Baynes et al. (2000)
6. Addington et al. (1996)
7. Bernard et al. (1998)
8. Lee et al. (2003)
9. Bressan et al. (1998)
10. Schuetze et al. (2001)
11. Sarro et al. (2004)
12. Schwartz-Stav et al. (2006)
13. Xiao et al. (2009)
14. Reine et al. (2000)
15. Liu et al. (2009)
16. Müller et al. (1999)
17. Kontaxakis et al. (2000a)
18. Kaneda et al. (2000)
19. Chemerinski et al. (2008)
20. Kuck et al. (1992)
21. Kontaxakis et al. (2000b)
22. Kontaxakis et al. (2002)
23. Lançon et al. (2000)
24. Collins et al. (1996)
25. Fitzgerald et al. (2002)
26. Kim et al. (2006)
27. El Yazaji et al. (2002)
28. Goldman et al. (1992)
29. Kitamura and Suga (1991)
30. Markou (1996)
31. Norman et al. (1998)
32. Addington et al. (1994)
33. Müller (2002)
34. Möser et al. (2006)
35. Huppert et al. (2002)
36. Lindenmayer et al. (1992)
37. Müller et al. (2006)

the six instruments. The HAMD was most frequently investigated (by 19 comparative studies), followed by the CDSS, PANSS-D, BDI, BPRS-D and MADRS. The highest concurrent validity indices were found for the CDSS and MADRS.

3.6. Predictive validity

Four studies evaluated whether the six depression instruments adequately predicted the presence of MDE in patients with schizophrenia. Table 3d illustrates that the highest ranges for sensitivity and specificity were found for the CDSS. Of note, the optimal cut-off values obtained for the CDSS and PANSS-D varied widely between studies.

4. Discussion

4.1. Summary of results

We identified five clinician-rated instruments and only one self-report with tested reliability and validity for the measurement of depressive symptoms in patients with schizophrenia.

4.2. Reliability

The reliability of the reviewed depression instruments was good in populations with schizophrenia and comparable to populations with depressed patients or healthy subjects (Müller et al., 2005; Rush et al., 2008). In other words, patients with schizophrenia can reliably be assessed on the presence of depressive symptoms by interview or self-report.

4.3. Validity

The instruments differed in their accuracy to distinguish depressive symptoms from other symptoms of schizophrenia (divergent validity). Correlation studies and factor analysis showed that the CDSS measures nearly no other symptoms of schizophrenia. Inspection of the items of the CDSS supported that the overlap with negative symptoms or EPS was minimal compared to the other depression instruments. The high divergent validity of the CDSS is in line with the fact that this instrument has especially been developed for this population (Addington et al., 1993). For example, “lack of interest” was not included, as this is both a symptom of depression and part of the negative symptoms of schizophrenia (Kulhara et al., 1989; Montgomery, 1979; Romney and Can-dido, 2001). Divergent validity of the other (older) instruments may be hampered as they are based on several items about anxiety or somatic concern (Snaith, 1993), albeit anxiety-like symptoms do not belong to the current DSM-IV diagnostic criteria for depression.

This wide variation of symptom dimensions covered by the reviewed instruments may explain the modest inter-correlations between most depression instruments. The low concurrent validity between instruments may even be over-estimated by the halo-effect. Ideally raters are not influenced by knowledge of the subject's scores on other instruments (Nisbett and DeCamp Wilson, 1977). However, in some studies multiple instruments for depressive symptoms were rated by a single rater (Lançon et al., 2000), or the distribution of

tasks among raters was unclear (El Yazaji et al., 2002; Kim et al., 2006).

The sensitivity and specificity to detect cases of depression in schizophrenia was highest for the CDSS, even though the CDSS did not cover all diagnostic criteria for depression as outlined above. Among the relatively scarce reports of predictive validity we noticed inconsistencies in the reported cut-off values for the PANSS-D and CDSS. Nevertheless we were able to compare the instruments on their predictive validity as we included only those studies with standardized procedures to obtain the optimal cut-off value (area under the curve methods).

4.4. Practical considerations

Practical issues such as time investment may also be important when choosing an instrument, apart from the psychometric aspects discussed above. The amount of training and time to complete the interview of the CDSS was comparable to the HAMD and MADRS. In contrast, the multidimensional instruments BPRS and PANSS may need more time and training to complete the interview, although an advantage may be that besides depressive symptoms, other psychotic symptoms can be evaluated at the same time.

4.5. Future research

An important finding was the lack of self-report instruments for the measurement of depressive symptoms in this population. The concurrent and predictive validity of the only reviewed self-report here BDI was rather poor. Especially for routine outcome monitoring of depressive symptoms in clinical practice, self-report may save time and costs compared to a clinical interview. Although filling out questionnaires may be difficult for patients with considerable cognitive problems (Addington et al., 1993; Müller et al., 2006; Norholm and Bech, 2006) and observable signs of depression could be missed by self-report (Möller, 2009), self-report may provide more independent information on the patients' experience of depression in schizophrenia than interview-based assessments (Lindenmayer et al., 1992). The literature search identified several other self-report questionnaires for depressive symptoms, such as the CES-D and the BSI (a short version of the Symptom Checklist-90). Evaluation of the composition of the BSI showed that only one of the six items of the depression subscale had potential overlap with negative symptoms [data not shown]. Future research is needed to develop and validate a self-report comparable to the CDSS with respect to reliability and validity in schizophrenia.

4.6. Recommendations and conclusions

In most of the reviewed studies the CDSS outperformed other depression instruments in terms of reliability and validity in patients with schizophrenia. Nevertheless the other depression instruments are still applied in schizophrenia research (Freudenreich et al., 2008; Heald et al., 2008; Möser et al., 2006; Saarni et al., 2010; Schennach-Wolff et al., 2010). This is in accordance to a survey under psychiatrists demonstrating the popularity of the HAMD, BDI and BPRS-D in daily practice (Siris et al., 2001). The current review may aid clinicians and

researchers to choose a well-validated instrument that selectively measures the symptoms of interest.

In summary, the CDSS was most reliable and valid for the measurement of depressive symptoms of schizophrenia. We recommend to use the CDSS in research as well as in daily clinical practice. Patients with a high score should be re-assessed using a diagnostic interview. As self-report is more expedient for the use in routine clinical practice, further research is needed to develop a self-reporting instrument with psychometric properties comparable to the CDSS.

Role of funding source

This study was supported by an unconditional grant from the Christian Fellowship of Care for Mental and Neurological Disorders (VCGZ) and the Dutch Foundation for Mental Health.

Conflict of interest

The authors have not transmitted any conflicts of interest.

I.M.L. received funding and speaker fees by AstraZeneca for a project unrelated to the current manuscript.

R.B. received speaker fees from AstraZeneca, Eli Lilly, and Janssen-Cilag.

H.K. received unconditional research grants from AstraZeneca, Eli Lilly, Janssen-Cilag and Bristol-Myers Squibb and has been working in advisory boards of Eli Lilly and Janssen-Cilag.

C.J.S. received an unconditional grant from Bristol-Myers Squibb for initiating the disease management program.

K.T. received speaker fees from B. Braun and Hosira.

R.S. and D.W. declared not to have any conflict of interest.

Acknowledgements

The authors wish to thank Truus van Ittersum for methodological advice.

References

- Addington, D., Addington, J., Maticka-Tyndale, E., 1993. Assessing depression in schizophrenia: the Calgary Depression Scale. *The British Journal of Psychiatry*. Supplement 39–44.
- Addington, D., Addington, J., Maticka-Tyndale, E., 1994. Specificity of the Calgary Depression Scale for schizophrenics. *Schizophrenia Research* 11, 239–244.
- Addington, D., Addington, J., Atkinson, M., 1996. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. *Schizophrenia Research* 19, 205–212.
- Allan, R., Martin, C.R., 2009. Can the Hospital Anxiety and Depression Scale be used in patients with schizophrenia? *Journal of Evaluation in Clinical Practice* 15, 134–141.
- Alves, T.M., Pereira, J.C., Elkis, H., 2005. The psychopathological factors of refractory schizophrenia. *Revista Brasileira de Psiquiatria* 27, 108–112.
- American Psychiatric Association, 1994. *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. American Psychiatric Association, Washington, DC.
- Andreasen, N.C., 1979. Affective flattening and the criteria for schizophrenia. *The American Journal of Psychiatry* 136, 944–947.
- Andreasen, N.C., 1982. Negative symptoms in schizophrenia. Definition and reliability. *Archives of General Psychiatry* 39, 784–788.
- Barnes, T.R., McPhillips, M.A., 1995. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. *International Clinical Psychopharmacology* 10 (Suppl 3), 115–121.
- Baynes, D., Mulholland, C., Cooper, S.J., Montgomery, R.C., MacFlynn, G., Lynch, G., Kelly, C., King, D.J., 2000. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. *Schizophrenia Research* 45, 47–56.
- Beck, A.T., Steer, R.A., Ball, R., Ranieri, W., 1996. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. *Journal of Personality Assessment* 67, 588–597.
- Bernard, D., Lancon, C., Auquier, P., Reine, G., Addington, D., 1998. Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients. *Acta Psychiatrica Scandinavica* 97, 36–41.
- Birchwood, M., Iqbal, Z., Chadwick, P., Trower, P., 2000. Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression. *The British Journal of Psychiatry* 177, 516–521.
- Bressan, R.A., Chaves, A.C., Shirakawa, I., de Mari, J., 1998. Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. *Schizophrenia Research* 32, 41–49.
- Bressan, R.A., Chaves, A.C., Pilowsky, L.S., Shirakawa, I., Mari, J.J., 2003. Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. *Psychiatry Research* 117, 47–56.
- Buckley, P.F., Miller, B.J., Lehrer, D.S., Castle, D.J., 2008. Psychiatric comorbidities and schizophrenia. *Schizophrenia Bulletin* 35, 383–402.
- Chemerinski, E., Bowie, C., Anderson, H., Harvey, P.D., 2008. Depression in schizophrenia: methodological artifact or distinct feature of the illness? *The Journal of Neuropsychiatry and Clinical Neurosciences* 20, 431–440.
- Cicchetti, D.V., 1994. Multiple comparison methods: establishing guidelines for their valid application in neuropsychological research. *Journal of Clinical and Experimental Neuropsychology* 16, 155–161.
- Collins, A.A., Remington, G., Coulter, K., Birkett, K., 1996. Depression in schizophrenia: a comparison of three measures. *Schizophrenia Research* 20, 205–209.
- Conley, R.R., Ascher-Svanum, H., Zhu, B., Faries, D.E., Kinon, B.J., 2007. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. *Schizophrenia Research* 90, 186–197.
- Craig, T.J., Richardson, M.A., Pass, R., Bregman, Z., 1985. Measurement of mood and affect in schizophrenic inpatients. *The American Journal of Psychiatry* 142, 1272–1277.
- Derogatis, L.R., Spencer, P.M., 1982. The Brief Symptom Inventory (BSI) Administration Scoring and Procedures Manual-I. In: Riderwood, M.D. (Ed.), *Clinical Psychometric Research*.
- Dingemans, P.M., Linszen, D.H., Lenior, M.E., Smeets, R.M., 1995. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). *Psychopharmacology* 122, 263–267.
- Eisenberg, D.P., Aniskin, D.B., White, L., Stein, J.A., Harvey, P.D., Galynker, I.I., 2009. Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: a confirmatory factor analysis of the positive and negative syndrome scale. *Psychopathology* 42, 242–248.
- El Yazaji, M., Battas, O., Agoub, M., Moussaoui, D., Gutknecht, C., Dalery, J., d'Amato, T., Saoud, M., 2002. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. *Schizophrenia Research* 56, 121–127.
- First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. The Structured Clinical Interview for DSM-III-R personality disorders (SCID-II), part I: description. *Journal of Personality Disorders* 9.
- Fitzgerald, P.B., Rolfe, T.J., Brewer, K., Filia, K., Collins, J., Filia, S., Adams, A., de Castella, A., Davey, P., Kulkarni, J., 2002. Depressive, positive, negative and parkinsonian symptoms in schizophrenia. *Aust. N.Z.J Psychiatry* 36, 340–346.
- Freudenreich, O., Tranulis, C., Cather, C., Henderson, D.C., Evins, A.E., Goff, D.C., 2008. Depressive symptoms in schizophrenia outpatients—prevalence and clinical correlates. *Clinical Schizophrenia & Related Psychoses* 2, 127–135.
- Goldman, R.S., Tandon, R., Liberzon, I., Greden, J.F., 1992. Measurement of depression and negative symptoms in schizophrenia. *Psychopathology* 25, 49–56.
- Häfner, H., 2000. Onset and early course as determinants of the further course of schizophrenia. *Acta Psychiatrica Scandinavica* 102, 44–48.
- Hamilton, M., 1960. A rating scale for depression. *Journal of Neurology, Neurosurgery, and Psychiatry* 23, 56–62.
- Hanley, J.A., McNeil, B.J., 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. *Radiology* 148, 839–843.
- Haro, J.M., Kamath, S.A., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M.J., Rele, R., Orta, J., Kharbeng, A., Araya, S., Gervin, M., Alonso, J., Mavreas, V., Lavrentzou, E., Lontos, N., Gregor, K., Jones, P.B., 2003. The Clinical Global Impression—Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. *Acta Psychiatrica Scandinavica*. Supplementum 16–23.
- Harrow, M., Yonan, C.A., Sands, J.R., Marengo, J., 1994. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? *Schizophrenia Bulletin* 20, 327–338.
- Heald, A., Morris, J., Soni, S.D., 2008. Characterisation of depression in patients with schizophrenia. *Indian Journal of Medical Research* 127, 544–550.
- Huppert, J.D., Smith, T.E., Apfeldorf, W.J., 2002. Use of self-report measures of anxiety and depression in outpatients with schizophrenia: reliability and validity. *Journal of Psychopathology and Behavioral Assessment* 24, 275–283.
- Kaneda, Y., Fujii, A., Ohmori, T., 2000. Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics. *The Journal of Nervous and Mental Disease* 188, 237–239.
- Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* 13, 261–276.

- Kay, S.R., Opler, L.A., Fiszbein, A., 2000. Positive and Negative Syndrome Scale (PANSS). Multi-Health Systems, Toronto.
- Kim, S.W., Kim, S.J., Yoon, B.H., Kim, J.M., Shin, I.S., Hwang, M.Y., Yoon, J.S., 2006. Diagnostic validity of assessment scales for depression in patients with schizophrenia. *Psychiatry Research* 144, 57–63.
- Kitamura, T., Suga, R., 1991. Depressive and negative symptoms in major psychiatric disorders. *Comprehensive Psychiatry* 32, 88–94.
- Kontaxakis, V.P., Havaki-Kontaxaki, B.J., Margariti, M.M., Stamouli, S.S., Kollias, C.T., Angelopoulos, E.K., Christodoulou, G.N., 2000a. The Greek version of the Calgary depression scale for schizophrenia. *Psychiatry Research* 94, 163–171.
- Kontaxakis, V.P., Havaki-Kontaxaki, B.J., Stamouli, S.S., Margariti, M.M., Kollias, C.T., Christodoulou, G.N., 2000b. Comparison of four scales measuring depression in schizophrenic inpatients. *European Psychiatry* 15, 274–277.
- Kontaxakis, V.P., Havaki-Kontaxaki, B.J., Stamouli, S.S., Margariti, M.M., Kollias, C.T., Christodoulou, G.N., 2002. Depression measures and motor side-effects in patients with acute schizophrenia. *Schizophrenia Research* 56, 197–198.
- Kopelowicz, A., Ventura, J., Liberman, R.P., Mintz, J., 2008. Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients. *Psychopathology* 41, 77–84.
- Kuck, J., Zisook, S., Moranville, J.T., Heaton, R.K., Braff, D.L., 1992. Negative symptomatology in schizophrenic outpatients. *The Journal of Nervous and Mental Disease* 180, 510–515.
- Kulhara, P., Avasthi, A., Chadda, R., Chandiramani, K., Mattoo, S.K., Kota, S.K., Joseph, S., 1989. Negative and depressive symptoms in schizophrenia. *The British Journal of Psychiatry* 154, 207–211.
- Lako, I.M., Taxis, K., Bruggeman, R., Knegtering, H., Burger, H., Wiersma, D., Slooff, C.J., 2011. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. *European Psychiatry*. doi:10.1016/j.eurpsy.2010.10.007.
- Lançon, C., Auquier, P., Reine, G., Bernard, D., Toumi, M., 2000. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). *Journal of Affective Disorders* 58, 107–115.
- Lee, K.H., Harris, A.W., Loughland, C.M., Williams, L.M., 2003. The five symptom dimensions and depression in schizophrenia. *Psychopathology* 36, 226–233.
- Leff, J., Tress, K., Edwards, B., 1988. The clinical course of depressive symptoms in schizophrenia. *Schizophrenia Research* 1, 25–30.
- Lindenmayer, J.P., Kay, S.R., Plutchik, R., 1992. Multivantaged assessment of depression in schizophrenia. *Psychiatry Research* 42, 199–207.
- Lindenmayer, J.P., Grochowski, S., Hyman, R.B., 1995. Five factor model of schizophrenia: replication across samples. *Schizophrenia Research* 14, 229–234.
- Liu, H., Zhang, H., Xiao, W., Liu, Q., Fu, P., Chen, J., Wang, G., Yang, F., Wang, G., Wang, X., Li, L., 2009. Scales for evaluating depressive symptoms in Chinese patients with schizophrenia. *The Journal of Nervous and Mental Disease* 197, 140–142.
- Loas, G., Noisette, C., Legrand, A., Delahousse, J., 1997. A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS. *Encephale* 23, 10–18.
- Lukoff, D., Liberman, R.P., Nuechterlein, K.H., 1986. Symptom monitoring in the rehabilitation of schizophrenic patients. *Schizophrenia Bulletin* 12, 578–602.
- Lykouras, L., Oulis, P., Psarros, K., Daskalopoulou, E., Botsis, A., Christodoulou, G.N., Stefanis, C., 2000. Five-factor model of schizophrenic psychopathology: how valid is it? *European Archives of Psychiatry and Clinical Neuroscience* 250, 93–100.
- Maggini, C., Raballo, A., 2006. Exploring depression in schizophrenia. *European Psychiatry* 21, 227–232.
- Markou, P., 1996. Depression in schizophrenia: a descriptive study. *The Australian and New Zealand Journal of Psychiatry* 30, 354–357.
- McMahon, R.P., Kelly, D.L., Kreyenbuhl, J., Kirkpatrick, B., Love, R.C., Conley, R.R., 2002. Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. *Neuropsychopharmacology* 26, 537–545.
- Möller, H.J., 2009. Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. *The World Journal of Biological Psychiatry* 10, 6–26.
- Montgomery, S.M., 1979. Depressive symptoms in acute schizophrenia. *Progress in Neuro-Psychopharmacology* 3, 429–433.
- Möser, C., Krieg, J.C., Zihl, J., Lautenbacher, S., 2006. Attention and memory deficits in schizophrenia: the role of symptoms of depression. *Cognitive and Behavioral Neurology* 19, 150–156.
- Müller, M.J., 2002. Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. *Schizophrenia Research* 57, 307.
- Müller, M.J., Marx-Dannigkeit, P., Schlosser, R., Wetzels, H., Addington, D., Benkert, O., 1999. The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). *Journal of Psychiatric Research* 33, 433–443.
- Müller, M.J., Brening, H., Gensch, C., Klinga, J., Kienzle, B., Müller, K.M., 2005. The Calgary Depression Rating Scale for schizophrenia in a healthy control group: psychometric properties and reference values. *Journal of Affective Disorders* 88, 69–74.
- Müller, M.J., Müller, K.M., Fellgiebel, A., 2006. Detection of depression in acute schizophrenia: sensitivity and specificity of 2 standard observer rating scales. *Canadian Journal of Psychiatry* 51, 387–392.
- Nisbett, R.E., DeCamp Wilson, T., 1977. The halo effect: evidence for unconscious alteration of judgments. *Journal of Personality and Social Psychology* 35, 250–256.
- Norholm, V., Bech, P., 2006. Quality of life in schizophrenic patients: association with depressive symptoms. *Nordic Journal of Psychiatry* 60, 32–37.
- Norman, R.M., Malla, A.K., 1991. Dysphoric mood and symptomatology in schizophrenia. *Psychological Medicine* 21, 897–903.
- Norman, R.M., Malla, A.K., Cortese, L., Diaz, F., 1998. Aspects of dysphoria and symptoms of schizophrenia. *Psychological Medicine* 28, 1433–1441.
- Overall, J.E., Henry, B.W., Markert, J.R., 1972. Validity of an empirically derived phenomenological typology. *Journal of Psychiatric Research* 9, 87–99.
- Radloff, L.S., 1977. The CES-D scale: a self-report depression scale for research in the general population. *Applied Psychology Measurement* 1, 385–401.
- Reine, G., Bernard, D., Auquier, P., Le Fur, B., Lançon, C., 2000. Psychometric properties of French version of the Calgary depression scale for schizophrenics (CDSS). *Encephale* 26, 52–61.
- Romney, D.M., Candido, C.L., 2001. Anhedonia in depression and schizophrenia: a reexamination. *The Journal of Nervous and Mental Disease* 189, 735–740.
- Ruggeri, M., Koeter, M., Schene, A., Bonetto, C., Vazquez-Barquero, J.L., Becker, T., Knapp, M., Knudsen, H.C., Tansella, M., Thornicroft, G., 2005. Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. *Schizophrenia Research* 75, 107–117.
- Rush, A.J., First, M.B., Blacker, D., 2008. *Handbook of Psychiatric Measures*, 2nd ed. American Psychiatric Publishing Inc, Washington, DC.
- Saarni, S.I., Viertio, S., Perala, J., Koskinen, S., Lonnqvist, J., Suvisaari, J., 2010. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. *The British Journal of Psychiatry* 197, 386–394.
- Sarro, S., Duenas, R.M., Ramirez, N., Arranz, B., Martinez, R., Sanchez, J.M., Gonzalez, J.M., Salo, L., Miralles, L., San, L., 2004. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. *Schizophrenia Research* 68, 349–356.
- Schennach-Wolff, R., Jager, M., Seemuller, F., Obermeier, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkotter, J., Heuser, I., Maier, W., Lemke, M.R., Ruther, E., Klingberg, S., Gastpar, M., Moller, H.J., Riedel, M., 2010. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. *Acta Psychiatrica Scandinavica* 121, 359–370.
- Schennach-Wolff, R., Obermeier, M., Seemuller, F., Jager, M., Messer, T., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkotter, J., Heuser, I., Maier, W., Lemke, M.R., Ruther, E., Klingberg, S., Gastpar, M., Moller, H.J., Riedel, M., 2011. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. *Acta Psychiatrica Scandinavica* 123, 228–238.
- Schuetz, T., Norholm, V., Raabaek Olsen, L., Hougaard, H., Ekstrom, M., Wagn, P., Bech, P., 2001. Reliability and validity of the Danish version of the Calgary Depression Scale for Schizophrenia. *Nordic Journal of Psychiatry* 55, 119–122.
- Schwartz-Stav, O., Apter, A., Zalsman, G., 2006. Depression, suicidal behavior and insight in adolescents with schizophrenia. *European Child & Adolescent Psychiatry* 15, 352–359.
- Simpson, G.M., Angus, J.W., 1970. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica. Supplementum* 212, 11–19.
- Siris, S.G., Bench, C., 2003. Depression and schizophrenia. In: Hirsch, S.R., Weinberger, D. (Eds.), *Schizophrenia*. Blackwell, Oxford, UK, pp. 140–167.
- Siris, S.G., Addington, D., Azorin, J.M., Falloon, I.R., Gerlach, J., Hirsch, S.R., 2001. Depression in schizophrenia: recognition and management in the USA. *Schizophrenia Research* 47, 185–197.
- Snaith, P., 1993. What do depression rating scales measure? *The British Journal of Psychiatry* 163, 293–298.
- Tollefson, G.D., Andersen, S.W., Tran, P.V., 1999. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. *Biological Psychiatry* 46, 365–373.
- Van Der Gaag, M., Hoffman, T., Remijsen, M., Hijman, R., De Haan, L., Van Meijel, B., Van Harten, P.N., Valmaggia, L., De Hert, M., Cuijpers, A., Wiersma, D., 2006. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. *Schizophrenia Research* 85, 280–287.

- Van Os, J., Kapur, S., 2009. Schizophrenia. *Lancet* 374, 635–645.
- Van Putten, T., May, R.P., 1978. "Akinetic depression" in schizophrenia. *Archives of General Psychiatry* 35, 1101–1107.
- White, L., Harvey, P.D., Opler, L., Lindenmayer, J.P., 1997. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. *Psychopathology* 30, 263–274.
- Widlocher, D.J., 1983. Psychomotor retardation: clinical, theoretical, and psychometric aspects. *The Psychiatric Clinics of North America* 6, 27–40.
- Wolthaus, J.E., Dingemans, P.M., Schene, A.H., Linszen, D.H., Knegtering, H., Holthausen, E.A., Cahn, W., Hijman, R., 2000. Component structure of the positive and negative syndrome scale (PANSS) in patients with recent-onset schizophrenia and spectrum disorders. *Psychopharmacology* 150, 399–403.
- Xiao, W., Liu, H., Zhang, H., Liu, Q., Fu, P., Chen, J., Wang, X., Wang, G., Li, L., Shu, L., 2009. Reliability and validity of the Chinese version of the Calgary Depression Scale for Schizophrenia. *The Australian and New Zealand Journal of Psychiatry* 43, 548–553.